- O-specific polysaccharide conjugates of shigellae were safe and immunogenic in young adults, and a Shigella sonnei conjugate conferred protection [1–3]. Shigellosis is primarily a disease of children; therefore, the safety and immunogenicity of S. sonnei and Shigella flexneri 2a conjugates were studied in 4- to 7-year-old children. Local and systemic reactions were minimal. The first injection of both conjugates elicited significant rises in geometric mean levels of serum IgG only to the homologous lipopolysaccharide (LPS) (S. sonnei, 0.32–8.25 ELISA units [EU]; S. flexneri 2a, 1.15–20.5 EU; P< .0001). Revaccination at 6 weeks induced a booster response to S. flexneri 2a LPS (20.5–30.5 EU, P = .003). Six months later, the geometric mean levels of IgG anti-LPS for both groups were higher than the prevaccination levels (P < .0001). Similar, but lesser, rises were observed for IgM and IgA anti-LPS. The investigational Shigella conjugates were safe and immunogenic in children and merit evaluation of their efficacy.